Keywords: Bayer, Rivaroxaban, Xarelto, Johnson & Johnson, EME, FDA

Bayer files for EU approval of anticoagulant rivaroxaban for stroke prevention; updates on US filing

Article | 06 January 2011

Print This

German drug major Bayer (BAY: DE) has submitted an application for marketing authorization to the European Medicines Agency (EMA) for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in